Zydus Cadila will get tentative nod from USFDA to market Parkinson’s illness drug

By: PTI | New Delhi |

Published: August 1, 2020 2:55:32 pm

The drug will likely be manufactured on the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Drug agency Zydus Cadila on Saturday mentioned it has obtained tentative nod from the US well being regulator to market Carbidopa and Levodopa extended-release capsules, used for the remedy of signs of Parkinson’s illness, within the US market.

The firm has obtained tentative approval from the United States Food and Drug Administration (USFDA) to market the capsules within the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg, Zydus Cadila mentioned in an announcement.

The drug will likely be manufactured on the group’s formulation manufacturing facility at SEZ, Ahmedabad, it added.

This medicine is used to deal with the signs of Parkinson’s illness similar to shakiness, stiffness, problem shifting or Parkinson-like circumstances, Zydus Cadila mentioned.

The group now has 295 approvals and has up to now filed over 390 abbreviated new drug functions (ANDAs) for the reason that graduation of its submitting course of, it added.

 

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and keep up to date with the most recent headlines

For all the most recent India News, obtain Indian Express App.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here